June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Glaucomatous progression in the African Descent and Glaucoma Evaluation Study (ADAGES)
Linda Zangwill; Naira Khachatryan; Sonia Jain; Feng He; Felipe Medeiros; Christopher Bowd; Renato Lisboa; Robert Weinreb; Jeffrey Liebmann; Christopher Girkin
Author Affiliations & Notes
  • Linda Zangwill
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, CA
  • Naira Khachatryan
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, CA
  • Sonia Jain
    Departmen of Family and Preventive Medicine, University of Cailfornia, San Diego, La Jolla, CA
  • Feng He
    Departmen of Family and Preventive Medicine, University of Cailfornia, San Diego, La Jolla, CA
  • Felipe Medeiros
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, CA
  • Christopher Bowd
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, CA
  • Renato Lisboa
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, CA
  • Robert Weinreb
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, CA
  • Jeffrey Liebmann
    New York University, New York, NY
    Ophthalmology, Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY
  • Christopher Girkin
    School of Medicine, University of Alabama-Birminghm, Birmingham, AL
  • Footnotes
    Commercial Relationships Linda Zangwill, Carl Zeiss Meditec Inc (F), Heidelberg Engineering GmbH (F), Optovue Inc (F), Topcon Medical Systems Inc (F), Nidek Inc (F); Naira Khachatryan, None; Sonia Jain, None; Feng He, None; Felipe Medeiros, Carl-Zeiss (F), Heidelberg Engineering (F), Topcon (F), Alcon (F), Allergan (F), Sensimed (F), Reichert (F); Christopher Bowd, None; Renato Lisboa, None; Robert Weinreb, Aerie (F), Alcon (C), Allergan (C), Altheos (C), Amakem (C), Bausch&Lomb (C), Carl Zeiss-Meditec (C), Genentech (F), Haag-Streit (F), Heidelberg Engineering (F), Konan (F), Lumenis (F), National Eye Institute (F), Nidek (F), Optovue (C), Quark (C), Solx (C), Topcon (C); Jeffrey Liebmann, Alcon Laboratories, Inc. (C), Allergan, Inc. (C), Allergan, Inc. (F), Carl Zeiss Meditech, Inc (F), Heidelberg Engineering, GmbH (F), Topcon Medical Systems, Inc. (F), National Eye Institute (F), New York Glaucoma Research Institute (F), SOLX, Inc. (C), Bausch & Lomb, Inc (C), Diopsys, Inc. (C), Diopsys, Inc. (F), Merz, Inc. (C), Glaukos, Inc. (C), Quark, Inc. (C); Christopher Girkin, SOLX (F), Heidelberg Engineering (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2655. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Glaucomatous progression in the African Descent and Glaucoma Evaluation Study (ADAGES)
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Linda Zangwill, Naira Khachatryan, Sonia Jain, Feng He, Felipe Medeiros, Christopher Bowd, Renato Lisboa, Robert Weinreb, Jeffrey Liebmann, Christopher Girkin; Glaucomatous progression in the African Descent and Glaucoma Evaluation Study (ADAGES). Invest. Ophthalmol. Vis. Sci. 2013;54(15):2655.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: To evaluate predictors of glaucomatous optic disc and visual field progression in glaucoma patients.

Methods: Glaucoma patients enrolled in the African Descent and Glaucoma Evaluation Study (ADAGES) and Diagnostic Innovations in Glaucoma Study (DIGS) with repeatable visual field damage at study entry followed for at least 2 years were included. Glaucomatous progression was defined as the development of Standard Automated Perimetry (SAP) Guided Progression Analysis (GPA) “likely progression” or stereophotograph-based optic disc deterioration identified by 2 independent graders. Age, gender, race, IOP and baseline ocular risk factors including corneal thickness, stereophotograph-based vertical cup-disc ratio and visual field MD and PSD were evaluated in univariate and multivariable Cox proportional hazards models to identify predictors of glaucomatous progression.

Results: 458 eyes of 254 glaucoma patients (130 African descent and 124 European descent) were included. The median SAP MD at study entry was -3.0db (range: -30.2 db to 1.4 db). The mean follow-up time was 5.7 years (range: 2.4 to 9.5 years). 100 (39%) of the 254 glaucoma patients progressed in at least one eye. 66 of the patients developed GPA visual field changes only, 19 developed optic changes only and 15 developed both visual field and optic disc changes during the follow-up period. The mean (+ SD) time to progression was 4.8 + 1.9 years. The proportion of participants progressing was similar in African descent (50/130, 38.9%) and European descent (50/124, 40.3%) glaucoma patients. In multivariable analysis, baseline IOP and stereophotograph based vertical cup disc ratio were independently predictive of glaucomatous progression.

Conclusions: In this subgroup of the ADAGES cohort with glaucomatous visual field damage at study entry, a relatively large proportion of African descent and European descent glaucoma patients showed evidence of GPA visual field changes and/or optic disc change.

Keywords: 464 clinical (human) or epidemiologic studies: risk factor assessment  
© 2013, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept